These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15632476)

  • 1. [Perspective of calcium antagonist].
    Kim-Mitsuyama S
    Clin Calcium; 2005 Jan; 15(1):81-6. PubMed ID: 15632476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Calcium antagonists: current and future applications based on new evidence. Classification of calcium channel blockers].
    Takahara A
    Clin Calcium; 2010 Jan; 20(1):24-30. PubMed ID: 20048430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium antagonists and sympathetic nerve activation: are there differences between classes?
    Noll G; Wenzel RR; Shaw S; Lüscher TF
    J Hypertens Suppl; 1998 Jan; 16(1):S17-24. PubMed ID: 9534092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of calcium channel blockers in atherosclerosis and cardiovascular event and oxidative vascular damage].
    Fujino T; Sumitomo K; Hasebe N; Kikuchi K
    Clin Calcium; 2004 Jan; 14(1):119-27. PubMed ID: 15576967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone and calcium update; research of calcium metabolism on cardiovascular system update. Calcium channel blocker update].
    Kim-Mitsuyama S
    Clin Calcium; 2011 Dec; 21(12):34-42. PubMed ID: 22133822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blockers in the treatment of disease.
    Elmslie KS
    J Neurosci Res; 2004 Mar; 75(6):733-41. PubMed ID: 14994334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pleiotropic effects of new generation calcium channel blockers on cardiovascular protections].
    Ogimoto A; Higaki J
    Clin Calcium; 2013 Apr; 23(4):569-74. PubMed ID: 23545747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-antagonist drugs.
    Abernethy DR; Schwartz JB
    N Engl J Med; 1999 Nov; 341(19):1447-57. PubMed ID: 10547409
    [No Abstract]   [Full Text] [Related]  

  • 10. [Calcium antagonists. Pharmacology and clinical pharmacology].
    Grobecker H
    Med Monatsschr Pharm; 1994 May; 17(5):130-9. PubMed ID: 8022361
    [No Abstract]   [Full Text] [Related]  

  • 11. Calcium channels and calcium channel blockers.
    Seth SD; Seth S
    Indian J Physiol Pharmacol; 1991 Oct; 35(4):217-31. PubMed ID: 1667398
    [No Abstract]   [Full Text] [Related]  

  • 12. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
    Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives.
    Jo MN; Seo HJ; Kim Y; Seo SH; Rhim H; Cho YS; Cha JH; Koh HY; Choo H; Pae AN
    Bioorg Med Chem; 2007 Jan; 15(1):365-73. PubMed ID: 17035033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How safe are calcium channel antagonists.
    Birbari AE
    J Med Liban; 1995; 43(3):120-1. PubMed ID: 8965311
    [No Abstract]   [Full Text] [Related]  

  • 16. [Calcium channel blocking agents: evaluation and perspectives].
    Lebrun P
    Rev Med Brux; 1988 Jun; 9(5):280-9. PubMed ID: 2457930
    [No Abstract]   [Full Text] [Related]  

  • 17. [Calcium antagonists in cardiologic practice (a review of the literature)].
    Andrushchenko EV; Malanchuk TA; Chmir VP
    Vrach Delo; 1990 May; (5):31-6. PubMed ID: 2204198
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ca channel blocker and heart failure].
    Kinugawa S; Tsutsui H
    Clin Calcium; 2005 Oct; 15(10):1615-22. PubMed ID: 16199906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The range of clinical use of current calcium antagonists].
    Sidorenko BA; Preobrazhenskiĭ LV
    Ter Arkh; 1998; 70(12):80-4. PubMed ID: 10067262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.